HIMSThursday, 4 Jun 2026
Canaccord Genuity reiterated its Buy rating with a $32 price target, built on peptide growth and the expansion of preventive healthcare
Canaccord Genuity reiterated its Buy rating with a $32 price target, built on peptide growth and the expansion of preventive healthcare. It is the first sell-side firm to reiterate a Buy since the Eucalyptus acquisition closed, and its target is among the highest of the analysts currently covering the stock.
Key facts
- Canaccord Genuity reiterates Buy with a $32 target (published 3 Jun)
- Core thesis: peptide growth and the expansion of preventive healthcare
- First sell-side firm to reiterate Buy since the Eucalyptus acquisition closed
- The sell side is split. Bulls: Canaccord at $32, Needham (Buy) and JPMorgan (Overweight). Neutral or bearish: BofA at $25, Leerink at $25 (which doubts margins on branded GLP-1s and sees 10% downside) and Deutsche Bank at $25
- The heart of the disagreement: Canaccord prices in expected peptide revenue and a re-rating of the platform, while peptides still contribute nothing in the Leerink and BofA models
- The FDA peptide advisory committee on 23-24 Jul will be the key arbiter
Show 2 more
- Digesting Eucalyptus: on 2 Jun, the day the acquisition closed, the shares rose 6.16% to $28.76, then gave back some of the gain on 3 Jun to $27.51 (down 0.90%)
- The market is weighing the $1.15 billion purchase price and the dilution from the $350 million convertible notes against the long-term value of 850,000 customers in five markets
A brief is a lead for our research, not a verified conclusion or advice.